Therapeutic Approaches Targeting MYC-Driven Prostate Cancer

Richard J Rebello^{1

2}, Richard B Pearson^{3

4

5

6}, Ross D Hannan^{7

8

9

10

11

12}, Luc Furic^{13

14

15}

Affiliations

¹ Prostate Cancer Translational Research Laboratory, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia. richard.rebello@monash.edu.
² Cancer Program, Biomedicine Discovery Institute and Department of Anatomy & Developmental Biology, Monash University, Melbourne, VIC 3800, Australia. richard.rebello@monash.edu.
³ Oncogenic Signalling and Growth Control Program, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia. rick.pearson@petermac.org.
⁴ Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC 3010, Australia. rick.pearson@petermac.org.
⁵ Department of Biochemistry and Molecular Biology, University of Melbourne, Parkville, VIC 3010, Australia. rick.pearson@petermac.org.
⁶ Department of Biochemistry and Molecular Biology, Monash University, Melbourne, VIC 3800, Australia. rick.pearson@petermac.org.
⁷ Oncogenic Signalling and Growth Control Program, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia. ross.hannan@anu.edu.au.
⁸ Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC 3010, Australia. ross.hannan@anu.edu.au.
⁹ Department of Biochemistry and Molecular Biology, University of Melbourne, Parkville, VIC 3010, Australia. ross.hannan@anu.edu.au.
¹⁰ Department of Biochemistry and Molecular Biology, Monash University, Melbourne, VIC 3800, Australia. ross.hannan@anu.edu.au.
¹¹ The ACRF Department of Cancer Biology and Therapeutics, The John Curtin School of Medical Research, The Australian National University, Acton, ACT 2601, Australia. ross.hannan@anu.edu.au.
¹² School of Biomedical Sciences, University of Queensland, Brisbane, QLD 4072, Australia. ross.hannan@anu.edu.au.
¹³ Prostate Cancer Translational Research Laboratory, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia. luc.furic@monash.edu.
¹⁴ Cancer Program, Biomedicine Discovery Institute and Department of Anatomy & Developmental Biology, Monash University, Melbourne, VIC 3800, Australia. luc.furic@monash.edu.
¹⁵ Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC 3010, Australia. luc.furic@monash.edu.

PMID: 28212321
PMCID: PMC5333060
DOI: 10.3390/genes8020071

Review

Therapeutic Approaches Targeting MYC-Driven Prostate Cancer

Richard J Rebello et al. Genes (Basel). 2017.

. 2017 Feb 16;8(2):71.

doi: 10.3390/genes8020071.

Authors

Richard J Rebello^{1

2}, Richard B Pearson^{3

4

5

6}, Ross D Hannan^{7

8

9

10

11

12}, Luc Furic^{13

14

15}

Affiliations

¹ Prostate Cancer Translational Research Laboratory, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia. richard.rebello@monash.edu.
² Cancer Program, Biomedicine Discovery Institute and Department of Anatomy & Developmental Biology, Monash University, Melbourne, VIC 3800, Australia. richard.rebello@monash.edu.
³ Oncogenic Signalling and Growth Control Program, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia. rick.pearson@petermac.org.
⁴ Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC 3010, Australia. rick.pearson@petermac.org.
⁵ Department of Biochemistry and Molecular Biology, University of Melbourne, Parkville, VIC 3010, Australia. rick.pearson@petermac.org.
⁶ Department of Biochemistry and Molecular Biology, Monash University, Melbourne, VIC 3800, Australia. rick.pearson@petermac.org.
⁷ Oncogenic Signalling and Growth Control Program, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia. ross.hannan@anu.edu.au.
⁸ Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC 3010, Australia. ross.hannan@anu.edu.au.
⁹ Department of Biochemistry and Molecular Biology, University of Melbourne, Parkville, VIC 3010, Australia. ross.hannan@anu.edu.au.
¹⁰ Department of Biochemistry and Molecular Biology, Monash University, Melbourne, VIC 3800, Australia. ross.hannan@anu.edu.au.
¹¹ The ACRF Department of Cancer Biology and Therapeutics, The John Curtin School of Medical Research, The Australian National University, Acton, ACT 2601, Australia. ross.hannan@anu.edu.au.
¹² School of Biomedical Sciences, University of Queensland, Brisbane, QLD 4072, Australia. ross.hannan@anu.edu.au.
¹³ Prostate Cancer Translational Research Laboratory, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia. luc.furic@monash.edu.
¹⁴ Cancer Program, Biomedicine Discovery Institute and Department of Anatomy & Developmental Biology, Monash University, Melbourne, VIC 3800, Australia. luc.furic@monash.edu.
¹⁵ Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC 3010, Australia. luc.furic@monash.edu.

PMID: 28212321
PMCID: PMC5333060
DOI: 10.3390/genes8020071

Abstract

The transcript encoding the proto-oncogene MYC is commonly overexpressed in prostate cancer (PC). MYC protein abundance is also increased in the majority of cases of advanced and metastatic castrate-resistant PC (mCRPC). Accordingly, the MYC-directed transcriptional program directly contributes to PC by upregulating the expression of a number of pro-tumorigenic factors involved in cell growth and proliferation. A key cellular process downstream of MYC activity is the regulation of ribosome biogenesis which sustains tumor growth. MYC activity also cooperates with the dysregulation of the phosphoinositol-3-kinase (PI3K)/AKT/mTOR pathway to promote PC cell survival. Recent advances in the understanding of these interactions through the use of animal models have provided significant insight into the therapeutic efficacy of targeting MYC activity by interfering with its transcriptional program, and indirectly by targeting downstream cellular events linked to MYC transformation potential.

Keywords: MYC; mouse models; prostate cancer; therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

**Figure 1**
Expression levels of MYC in 5-month-old Hi-MYC (ARR2Pbsn-MYC), PTEN-null (PTEN^Fl/Fl;Pbsn-Cre) and FVB/N (Wild type) prostate. MYC is overexpressed in Hi-MYC but also elevated in PTEN null prostate carcinoma.

See this image and copyright information in PMC

References

1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2016. CA Cancer J. Clin. 2016;66:7–30. doi: 10.3322/caac.21332. - DOI - PubMed
1. Karantanos T., Corn P.G., Thompson T.C. Prostate cancer progression after androgen deprivation therapy: Mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. 2013;32:5501–5511. doi: 10.1038/onc.2013.206. - DOI - PMC - PubMed
1. Trewartha D., Carter K. Advances in prostate cancer treatment. Nat. Rev. Drug Discov. 2013;12:823–824. doi: 10.1038/nrd4068. - DOI - PubMed
1. Humphrey P.A. Gleason grading and prognostic factors in carcinoma of the prostate. Mod. Pathol. 2004;17:292–306. doi: 10.1038/modpathol.3800054. - DOI - PubMed
1. McNeal J.E. The zonal anatomy of the prostate. Prostate. 1981;2:35–49. doi: 10.1002/pros.2990020105. - DOI - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Therapeutic Approaches Targeting MYC-Driven Prostate Cancer

Affiliations

Therapeutic Approaches Targeting MYC-Driven Prostate Cancer

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

References

Publication types

LinkOut - more resources

Full Text Sources

Other Literature Sources

Miscellaneous